irinotecan has been researched along with cryptotanshinone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Chan, RL; Cho, CH; Hu, T; Li, M; Lu, L; Shen, J; To, KK; Wang, L; Yeung, JH; Zhang, L | 1 |
Du, GH; Wang, L; Wang, R; Wang, SM; Wang, Z; Wei, GY; Zhang, RP; Zhu, Y | 1 |
2 other study(ies) available for irinotecan and cryptotanshinone
Article | Year |
---|---|
Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza.
Topics: Abietanes; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Caco-2 Cells; Camptothecin; Digoxin; Doxorubicin; Drugs, Chinese Herbal; Furans; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Phenanthrenes; Quinones; Salvia miltiorrhiza | 2014 |
Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Bacteria; Colitis; Colon; Colonic Neoplasms; Feces; Fluorouracil; Gastrointestinal Microbiome; Irinotecan; Lipid Metabolism; Male; Mice, Inbred BALB C; Phenanthrenes; RNA, Ribosomal, 16S | 2021 |